Protein and Peptide-Based Therapeutics Trending the Global Orally
Disintegrating Tablets Market
In a new report titled ‘Orally Disintegrating Tablets Market: Global Industry Analysis
2012 – 2016 and Forecast 2017 – 2025,’ Persistence Market Research studies the
performance of the global orally disintegrating tablets market over an eight year
period from 2017 to 2025 and presents a detailed forecast of the market both for the
historical period 2012 – 2016 as well as for the forecasted period of 2017 – 2025.
According to Persistence Market Research, the global orally disintegrating tablets
market is predicted to grow at a significant pace during the assessment period owing
to a rising preference for orally disintegrating tablets among patients and physicians
alike; coupled with the fact that orally disintegrating tablets minimize the scope for
dosage errors and are ideal for administering to patients of all age groups. These
factors are likely to boost revenue growth of the global orally disintegrating tablets
market, which is anticipated to rise from an estimated US$ 11.4 Bn in 2017 to about
US$ 27 Bn by the end of 2025, witnessing a CAGR of 11.5% in terms of value
during the forecast period.
Request to view table of content @
https://www.persistencemarketresearch.com/market-research/orallydisintegrating-tablet-market/toc
In this report, Persistence Market Research segments the global orally disintegrating
tablets market on the basis of drug class, disease indication, distribution channel, and
region.
Global Orally Disintegrating Tablets Market, Forecast by Drug Class
In terms of drug class, the global orally disintegrating tablets market is further
segmented into Anti-Psychotics, Anti-Epileptics, CNS Stimulants, Anxiolytics, AntiParkinsonian Drugs, Anti-Hypertensives, NSAIDS, Anti-Allergy Drugs, Proton Pump
Inhibitor, and Others. Anti-Psychotics drug class will be the reigning segment in
terms of market revenue share throughout the forecast period, anticipated to hold
about 20% revenue share of the global market by 2025 end. With a noteworthy 15.7%
CAGR, this segment will retain its supremacy over other drug class segments during
the eight year period.
Global Orally Disintegrating Tablets Market, Forecast by Disease Indication
Under this category, the global market is segmented into Central Nervous System
(CNS) Diseases, Gastrointestinal (GI) Diseases, Cardiovascular (CVS) Diseases,
Allergy, and Others. CNS Diseases segment will hold maximum revenue share in the
global market, and Persistence Market Research forecasts indicate a 55% market
share for this segment by the end of the forecast period in 2025. The CNS Diseases
segment is forecasted to reach a market valuation of about US$ 15 Bn by 2025 end,
registering a CAGR of 13.2%. This is slated to be the most dominant segment by
disease indication in the global orally disintegrating tablets market.
A sample of this report is available upon request @
https://www.persistencemarketresearch.com/samples/14572
Global Orally Disintegrating Tablets Market, Forecast by Distribution Channel
Of the various distribution channels of orally disintegrating tablets viz., Hospital
Pharmacies, Retail Pharmacies, Drug Stores, and Online Pharmacies, Hospital
Pharmacies will be the undisputed leader in terms of market share throughout the
forecast period, anticipated to account for nearly 49% value share by the end of 2025.
A market valuation of about US$ 13 Bn by the end of 2025 with a 13.2% CAGR is
likely to be in store for this segment.
Global Orally Disintegrating Tablets Market, Regional Forecast
Persistence Market Research tracks the performance of the global orally
disintegrating tablets market across the key geographies of North America, Latin
America, Europe, Asia Pacific, and Middle East & Africa. North America is slated to
dominate the global market throughout the forecast period, with an estimated 35%
market share and a market value of about US$ 9.7 Bn by the end of 2025. This is
reflective of a CAGR of 11.7% during the forecast period.
The report profiles some of the leading companies operating in the global orally
disintegrating tablets market such as Teva Pharmaceutical Industries Ltd., Novartis
AG, AstraZeneca, Mylan N.V., Pfizer Inc., Johnson & Johnson Services, Inc., F.
Hoffmann-La Roche Ltd., Merck & Co., Inc., Valeant, GlaxoSmithKline plc., Sun
Pharmaceutical Industries Ltd., Bayer AG, Eli Lilly and Company, Dr. Reddy’s
Laboratories Ltd, Takeda Pharmaceutical Company Limited, Eisai Co., Ltd., Zydus
Cadila, NEOS Therapeutics, Inc., Glenmark, and Unichem Laboratories.
Browse Complete Report @
https://www.persistencemarketresearch.com/market-research/orallydisintegrating-tablet-market.asp
About Us:
Persistence Market Research (PMR) is a third-platform research firm. Our research
model is a unique collaboration of data analytics and market research methodology to
help businesses achieve optimal performance.
To support companies in overcoming complex business challenges, we follow a
multi-disciplinary approach. At PMR, we unite various data streams from multidimensional sources. By deploying real-time data collection, big data, and customer
experience analytics, we deliver business intelligence for organizations of all sizes.
Our offerings include pre-built reports that address every major sale, customized
solutions to cater to client-specific needs, and consulting services to offer more value
addition. Our next-generation research approach for exploring emerging technologies
has allowed us to solve the most complex problems of clients. We do not follow a
reactive approach, but a pro-active one. Expert analysts at PMR keep a tab on nextgeneration technologies in their R&D phase and provide the latest insights into these
technologies when they are being commercialized. Our ground-breaking approach
allows us to deliver market solutions before the technologies reach the market.
Our client success stories feature a range of clients from Fortune 500 companies to
fast-growing startups. PMR’s collaborative environment is committed to building
industry-specific solutions by transforming data from multiple streams into a strategic
asset.
Contact Us:
Persistence Market Research
305 Broadway,7th Floor
New York City, NY 10007
United States
Tel: +1-646-568-7751
Email: [email protected]
Website: http://www.persistencemarketresearch.com/
[email protected]